Design and synthesis of resveratrol–salicylate hybrid derivatives as CYP1A1 inhibitors

References

• Guengerich FP, Shimada T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res-Fundam Mol Mech Mutag 1998;400:201–13
   PubMed Web of Science ®Google Scholar
• Sakaki T. Practical application of cytochrome P450. Biol Pharm Bull 2012;35:844–9
   PubMed Web of Science ®Google Scholar
• Oyama T, Kagawa N, Kunugita N, et al. Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 2004;9:1967–76
   PubMed Web of Science ®Google Scholar
• Bieche I, Narjoz C, Asselah T, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007;17:731–42
   PubMed Web of Science ®Google Scholar
• Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 2004;95:1–6
   PubMed Web of Science ®Google Scholar
• Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 2009;9:187
   PubMed Web of Science ®Google Scholar
• Nandekar PP, Sangamwar AT. Cytochrome P450 1A1-mediated anticancer drug discovery: in silico findings. Exp Opin Drug Discov 2012;7:771–89
   PubMed Web of Science ®Google Scholar
• Shanmugam MK, Kannaiyan R, Sethi G. Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer. Nutr Cancer Int J 2011;63:161–73
   PubMed Web of Science ®Google Scholar
• Schwarz D, Roots I. In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1. Biochem Biophys Res Commun 2003;303:902–7
   PubMed Web of Science ®Google Scholar
• Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 1999;262:20–4
   PubMed Web of Science ®Google Scholar
• Abbadessa G, Spaccamiglio A, Sartori ML, et al. The aspirin metabolite, salicylate, inhibits 7,12-dimethylbenz[a]anthracene-DNA adduct formation in breast cancer cells. Int J Oncol 2006;28:1131–40
   PubMed Web of Science ®Google Scholar
• MacDonald CJ, Cheng RYS, Roberts DD, et al. Modulation of carcinogen metabolism by nitric oxide-aspirin 2 is associated with suppression of DNA damage and DNA adduct formation. J Biol Chem 2009;284:22099–107
   PubMed Web of Science ®Google Scholar
• Pettit GR, Melody N, Thornhill A, et al. Antineoplastic agents. 579. Synthesis and cancer cell growth evaluation of E-stilstatin 3: a resveratrol structural modification. J Nat Prod 2009;72:1637–42
   PubMed Web of Science ®Google Scholar
• Flaherty DP, Walsh SM, Kiyota T, et al. Polyfluorinated bis-styrylbenzene beta-Amyloid plaque binding ligands. J Med Chem 2007;50:4986–92
   PubMed Web of Science ®Google Scholar
• Mao JL, Ran XK, Tian JZ, et al. Design, synthesis and biological evaluation of novel 4-hydroxybenzene acrylic acid derivatives. Bioorg Med Chem Lett 2011;21:1549–53
   PubMed Web of Science ®Google Scholar
• Gabriele B, Benabdelkamel H, Plastina P, et al. Trans-resveratrol-d(4), a molecular tracer of the wild-type phytoalexin; Synthesis and spectroscopic properties. Synthesis-Stuttgart 2008;18:2953–6
   Web of Science ®Google Scholar
• Murias M, Handler N, Erker T, et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Biorg Med Chem 2004;12:5571–78
   PubMed Web of Science ®Google Scholar
• Gill MT, Bajaj R, Chang CJ, et al. 3,3′,5′-Tri-O-methylpiceatannol and 4,3′,5′-tri-O-methylpiceatannol – improvements over piceatannol in bioactivity. J Nat Prod 1987;50:36–40
   PubMed Web of Science ®Google Scholar
• Hansen HC, Chiacchia FS, Patel R, et al. Stilbene analogs as inducers of apolipoprotein-I transcription. Eur J Med Chem 2010;45:2018–23
   PubMed Web of Science ®Google Scholar
• Sudan S, Rupasinghe HP. Flavonoid-enriched apple fraction AF4 induces cell cycle arrest, DNA topoisomerase II inhibition and apoptosis in human liver cancer HepG2 cells. Nutr Cancer 2014;66:1–10
   PubMed Web of Science ®Google Scholar
• El Gendy MAM, El-Kadi AOS. Harman induces CYP1A1 enzyme through an aryl hydrocarbon receptor mechanism. Toxicol Appl Pharmacol 2010;249:55–64
   PubMed Web of Science ®Google Scholar
• El Gendy MAM, El-Kadi AOS. Peganum harmala L. differentially modulates cytochrome P450 gene expression in human hepatoma HepG2 cells. Drug Metab Lett 2009;3:212–16
   PubMedGoogle Scholar
• Lorenzen A, Kennedy SW. A fluorescence-based protein assay for use with a microplate reader. Anal Biochem 1993;214:346–8
   PubMed Web of Science ®Google Scholar
• El Gendy MAM, Soshilov AA, Denison MS, El-Kadi AOS. Transcriptional and posttranslational inhibition of dioxin-mediated induction of CYP1A1 by harmine and harmol. Toxicol Lett 2012;208:51–61
   PubMed Web of Science ®Google Scholar
• El Gendy MAM, Soshilov AA, Denison MS, El-Kadi AOS. Harmaline and harmalol inhibit the carcinogen-activating enzyme CYP1A1 via transcriptional and posttranslational mechanisms. Food Chem Toxicol 2012;50:353–62
   PubMed Web of Science ®Google Scholar
• Anwar-Mohamed A, Elshenawy OH, Soshilov AA, et al. Methylated pentavalent arsenic metabolites are bifunctional inducers, as they induce cytochrome P450 1A1 and NAD(P)H:quinone oxidoreductase through AhR- and Nrf2-dependent mechanisms. Free Radic Biol Med 2014;67:171–187
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 2001;25:402–8
   PubMed Web of Science ®Google Scholar
• Aparicio O, Geisberg JV, Sekinger E, et al. Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Los Angeles: John Willey & Sons; 2005: chapter 21–3
   Google Scholar
• Walsh AA, Szklarz GD, Scott EE. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem 2013;288:12932–43
   PubMed Web of Science ®Google Scholar
• Bernstein FC, Koetzle TF, Williams GJB, et al. The protein data bank: a computer-based archival file for macromolecular structures. J Mol Biol 1977;112:535–42
   PubMed Web of Science ®Google Scholar
• Wang JM, Wang W, Kollman PA, Case DA. Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 2006;25:247–60
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF chimera – a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605–12
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91
   PubMed Web of Science ®Google Scholar
• Murphy PJ, Brennan J. The Wittig olefination reaction with carbonyl-compounds other than aldehydes and ketones. Chem Soc Rev 1988;17:1–30
   Web of Science ®Google Scholar
• Gester S, Wuest F, Pawelke B, et al. Synthesis and biodistribution of an 18F-labelled resveratrol derivative for small animal positron emission tomography. Amino Acids 2005;29:415–28
   PubMed Web of Science ®Google Scholar
• Solladie G, Pasturel-Jacope Y, Maignan J. A re-investigation of resveratrol synthesis by Perkins reaction. Application to the synthesis of aryl cinnamic acids. Tetrahedron 2003;59:3315–21
   Web of Science ®Google Scholar
• Dhyani MV, Kameswaran M, Korde AG, et al. Stereoselective synthesis of an iodinated resveratrol analog: preliminary bioevaluation studies of the radioiodinated species. Appl Radiat Isot 2011;69:996–1001
   PubMed Web of Science ®Google Scholar
• Beedanagari SR, Bebenek I, Bui P, Hankinson O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol Sci 2009;110:61–7
   PubMed Web of Science ®Google Scholar
• Mikstacka R, Baer-Dubowska W, Wieczorek M, Sobiak S. Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities. Mol Nutr Food Res 2008;52:S77–83
   PubMed Web of Science ®Google Scholar
• Regev-Shoshani G, Shoseyov O, Kerem Z. Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4. Biochem Biophys Res Commun 2004;323:668–73
   PubMed Web of Science ®Google Scholar
• Mikstacka R, Przybylska D, Rimando AM, Baer-Dubowska W. Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mol Nutr Food Res 2007;51:517–24
   PubMed Web of Science ®Google Scholar
• Kim S, Ko H, Park JE, et al. Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem 2001;45:160–4
   Web of Science ®Google Scholar
• MacDonald CJ, Ciolino HP, Yeh GC. The drug salicylamide is an antagonist of the aryl hydrocarbon receptor that inhibits signal transduction induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res 2004;64:429–34
   PubMed Web of Science ®Google Scholar
• Mikstacka R, Rimando AM, Dutkiewicz Z, et al. Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1. Biorg Med Chem 2012;20:5117–26
   PubMed Web of Science ®Google Scholar
• Shimada T, Inoue K, Suzuki Y, et al. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis 2002;23:1199–207
   PubMed Web of Science ®Google Scholar
• de Medina P, Casper R, Savouret JF, Poirot M. Synthesis and biological properties of new stilbene derivatives of resveratrol as new selective aryl hydrocarbon modulators. J Med Chem 2005;48:287–91
   PubMed Web of Science ®Google Scholar
• Stierand K, Rarey M. Drawing the PDB: protein-ligand complexes in two dimensions. ACS Med Chem Lett 2010;1:540–5
   PubMed Web of Science ®Google Scholar
• Paul S, Mizuno CS, Lee HJ, et al. In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer. Eur J Med Chem 2010;45:3702–8
   PubMed Web of Science ®Google Scholar